Notable highlights in 2021 include:
- Published compelling preclinical data from Yale University in The Journal of Clinical Investigation—Insight confirming the ability of PAT-DX1 to cross the blood-brain barrier, and supporting its potential to be used for primary and secondary brain cancers.
- Announced a successful preclinical study from the Garvan Institute showing that PAT-DX1 is able to slow tumour growth and increase survival in an animal model of pancreatic cancer.
- Released new data demonstrating that PAT-DX3 can be used as a targeting agent for antibody drug conjugates (ADC) to deliver anti-cancer drugs to tumours in an animal model.
- Established a collaboration with Imagion Biosystems to develop new, improved imaging agents for brain cancers using Patrys’ deoxymabs.
- Expanded Patrys’ intellectual property portfolio with the granting of a US patent for our deoxymab assets.
- A successful $7.8 million capital raise to support further research and development activities.
- Forums
- ASX - By Stock
- PAB
- Ann: Change of Director's Interest Notices x2
Ann: Change of Director's Interest Notices x2, page-79
Featured News
Add PAB (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $6.172M |
Open | High | Low | Value | Volume |
0.3¢ | 0.4¢ | 0.3¢ | $93.83K | 24.69M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
48 | 43730050 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 11827084 | 14 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
48 | 43730050 | 0.003 |
28 | 35223000 | 0.002 |
13 | 45751998 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 11827084 | 14 |
0.005 | 5004512 | 8 |
0.006 | 9044918 | 10 |
0.007 | 6226356 | 3 |
0.008 | 665910 | 2 |
Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
Featured News
PAB (ASX) Chart |